SCHEMBL29487409

SCHEMBL29487409

COc1ccc2c(c1)C1(CC1)C(=O)N2

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 2/20 0.55
AKR1B1 P15121 1/20 0.49
PGR P06401 3/20 0.49
PDE3B Q13370 3/20 0.46
PDE3A Q14432 3/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
ALDH1A1 P00352 1/20 0.46
AURKB Q96GD4 2/20 0.44
PLK4 O00444 1/20 0.44
OTUD7B Q6GQQ9 1/20 0.44
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28578842 1.00 PDE7A (0.55) PDE7AAKR1B1PGRPDE3BPDE3A
SCHEMBL4717250 0.92 PDE7A (0.62) PDE7AAKR1B1PGRPDE3BPDE3A
SCHEMBL23778428 0.91 PDE7A (0.50) PDE7AAKR1B1PGRPDE3BPDE3A
SCHEMBL4263093 0.91 PDE7A (0.50) PDE7AAKR1B1PGRPDE3BPDE3A
SCHEMBL8320710 0.88 AKR1B1 (0.49) PDE7AAKR1B1PGRPDE3BPDE3A
SCHEMBL31191374 0.87 PDE7A (0.55) PDE7AAKR1B1PGRPDE3BPDE3A
SCHEMBL4263460 0.84 IP6K1 (0.51) PDE7AAKR1B1PGRPDE3BPDE3A
SCHEMBL4263461 0.84 IP6K1 (0.51) PDE7AAKR1B1PGRPDE3BPDE3A
SCHEMBL29541573 0.83 AKR1B1 (0.47) PDE7AAKR1B1PGRPDE3BPDE3A
SCHEMBL5336043 0.82 PDE7A (0.48) PDE7AAKR1B1PGRPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598912-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2025-08-13 EP disclosed
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 US disclosed
WO-2024076891-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2024-04-11 WO disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 CN disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 US disclosed
CN-115677682-B Spiro PLK4 inhibitor and application thereof 上海齐鲁制药研究中心有限公司 2023-07-18 CN disclosed
EP-3283482-B1 PLK4 INHIBITORS LUDWIG INST FOR CANCER RES LTD (CH) 2022-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 PDE7A 1481/4885AKR1B1 1751/4885PGR 1920/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 PDE7A 1481/4885AKR1B1 1751/4885PGR 1920/4885
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 PDE7A 1481/4885AKR1B1 1751/4885PGR 1920/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 PDE7A 1481/4885AKR1B1 1751/4885PGR 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.